Amiodarone and Parkinsonism: a pharmacovigilance study.

Abstract

BACKGROUND:

Some case reports have described parkinsonism with amiodarone. We investigated a putative association between parkinsonism and exposure to amiodarone.

METHODS:

We used the WHO pharmacovigilance database (VigiBase® ). All adverse drug reactions with 'Parkinson-like events' and amiodarone were included. Four disproportionality analyses were performed: 1/after inclusion of all reports, 2/according to sex, 3/for the twenty last years (2000-2019), and 4/after exclusion of concomitant drugs known to induce parkinsonism (antipsychotic, antivertigo, antiemetic antinauseant drugs, flunarizine). Results are expressed as reporting odds ratios (ROR; 95% CI) and information component (IC).

RESULTS:

No significant association was found in the whole population [ROR = 0.83 (0.65-1.06), IC = -0.7 (IC025  = -0.65)], in men, in women, for the 2000-2019 years, or after exclusion of drugs inducing parkinsonism.

CONCLUSION:

We failed to find any signal of parkinsonism with amiodarone. We suggest that reports of parkinsonism with amiodarone could be mainly explained by other underlying causes.

• Authors: Jean-Louis Montastruc, Geneviève Durrieu
• Journal: Fundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 35 Issue 4 Pg. 781-784 (Aug 2021) ISSN: 1472-8206 [Electronic] England
• PMID: 33098706 (Publication Type: Journal Article)
• Copyright: © 2020 Société Française de Pharmacologie et de Thérapeutique.

Chemical References

• Anti-Arrhythmia Agents
• Amiodarone

Topics

• Adverse Drug Reaction Reporting Systems
• Aged
• Aged, 80 and over
• Amiodarone (adverse effects)
• Anti-Arrhythmia Agents (adverse effects)
• Databases, Factual
• Drug-Related Side Effects and Adverse Reactions (epidemiology)
• Female
• France (epidemiology)
• Humans
• Male
• Middle Aged
• Parkinsonian Disorders (chemically induced)
• Pharmacovigilance